Skip to main content
Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study
Published Web Location
http://europepmc.org/articles/PMC4140547?pdf=renderNo data is associated with this publication.
Abstract
This exploratory phase II study evaluated the safety and efficacy of belatacept in de novo adult liver transplant recipients. Patients were randomized (N=260) to one of the following immunosuppressive regimens: (i) basiliximab+belatacept high dose [HD]+myc
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.